Pall Corporation Introduces the PallSepTM Biotech Filtration System for Difficult-to-Process Biotechnology Feed Streams

Pall Corporation Introduces the PallSepTM Biotech Filtration System for Difficult-to-Process Biotechnology Feed Streams
System Delivers Gentle Separation for Harvest and Clarification Applications


PORT WASHINGTON, N.Y., February 02, 2010 - Pall Corporation (NYSE: PLL), a global leader in filtration, separation and purification, has introduced the PallSep Biotech system for the gentle separation of target molecules from complex biotechnology process fluids. The new system utilizes vibrating membrane filtration (VMF) technology and encapsulated hydrophilic polyethersulfone membrane filter modules. This unique combination reduces the accumulation of retained species on the membrane surface which allows for increased transmission of the target molecule.

The VMF principle is based on the rapid oscillation of porous membrane plates within a process feed stream to create shear at the membrane surface. The generated shear forces are limited to a narrow portion of the flow channel, reducing the amount of process fluid exposed to the shear. The cross flow requirements are much lower with the PallSep Biotech system than with other tangential flow filtration (TFF) technologies. This creates gentle processing and good product transmission.

The PallSep Biotech system supports the production of high value products like therapeutic vaccines and antigen extracts. It permits the concentration, clarification and purification of feed streams with high levels of biomass particulates and viscosity, along with difficult-to-filter solutions such as fermentation broths and lysates.

"The new PallSep Biotech system expands processing options by allowing users to combine different process steps such as harvest and clarification within the same system, thus simplifying the process design," said Nathalie Pathier, TFF product manager, Pall Life Sciences. "The stable permeate flow and improved protein transmission we can achieve with this technology contribute to better process economics."

The encapsulated 0.2 µm polyethersulfone membrane filter modules, available in filter areas of 0.2, 1 and 5 m2, offer flexibility for scale up and scale down of processes. Typical batch sizes range from a few liters to 500 liters, depending on the process application.

Custom designed for specific requirements, the PallSep Biotech system can be operated manually or within an automated process. It includes all valves, pumps, sensors, vessel and piping elements in a process system. GMP requirements for biopharmaceutical processes are met without compromising ease of use, flexibility, cleanability, safety or operating costs.

To learn more about the PallSep Biotech system, visit www.pall.com/biopharm. PallSep Biotech systems are available through Pall Life Sciences and can be ordered by phone at 1-800-717-7255 in the U.S. or +41 (0)26 350 53 00 in Europe. For a complete listing of international offices visit Pall online at www.pall.com/contact.

Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Pall technologies are also used to collect and process blood components and help protect patients from hospital-acquired infections. The company's membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce.

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing Total Fluid ManagementSM solutions to meet the critical needs of customers in biopharmaceutical, hospital and transfusion medicine, energy and alternative energy, electronics, municipal and industrial water, aerospace, transportation and broad industrial markets. Together with our customers, we foster health, safety and environmentally responsible technologies. The Company's engineered solutions enable process and product innovation and minimize emissions and waste. Pall Corporation, with total revenues of $2.3 billion for fiscal 2009, is an S&P 500 company with more than 10,000 employees servicing customers worldwide. Pall has been named a top "green company" by Newsweek magazine. To see how Pall is helping enable a greener and more sustainable future, visit www.pall.com.

Note to Editors: A high-resolution photograph of the PallSep Biotech System is available for download at www.pall.com/news

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6162976&lang=en

 

Pall Life Sciences
Carol Flint, 734-913-6432
Global V.P. Marketing Communications
[email protected]

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.